Bausch + Lomb Enrolls First Patient in a Trifocal IOL Clinical Trial
Monday, June 18, 2018 12:15 AM
BRIDGEWATER, N.J.—Bausch + Lomb
, a global eye health company and a division of Valeant Pharmaceuticals International
, has enrolled the first patient in a clinical trial studying the efficacy and safety of an investigational trifocal intraocular lens (IOL). The study is intended to support a pre-market approval application filing for the lens, the enVista MX60EF, according to a recent B+L announcement. If approved by the FDA, the enVista MX60EF trifocal IOL would become the latest addition to Bausch + Lomb’s enVista family of IOLs.
There are no FDA-approved trifocal IOLs available in the U.S. at this time, according to a B+L spokeswoman.
The enVista MX60EF trifocal IOL is a single-piece, ultra-violet absorbing posterior chamber IOL being developed to replace the natural crystalline lens in adult patients in whom the cataractous lens has been removed and who desire improved uncorrected near, intermediate and distance vision, according to the announcement.
“The initiation of this trial is an important milestone for our organization and another example of our commitment to investing in research and innovation,” Chuck Hess, B+L’s vice president and general manager, U.S. Surgical, said in the announcement. “We look forward to providing surgeons with another next-generation posterior chamber intraocular lens designed to meet their rapidly evolving needs.”